At a glance
- Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic peptide marketed as a topical, needle-free option for softening expression lines.
- It is modeled on waglerin-1, a peptide from temple viper venom that blocks the nerve-to-muscle receptor.
- Evidence for the cosmetic ingredient comes mostly from laboratory and manufacturer data rather than independent human trials.
- As with other "Botox-like" peptides, whether Syn-Ake penetrates intact skin to reach muscle is uncertain.
- Evidence strength: Limited, a synthetic peptide modeled on snake-venom waglerin-1 with mostly in-vitro and manufacturer data.
What is Syn-Ake?
Syn-Ake is a brand name for dipeptide diaminobutyroyl benzylamide diacetate, a small synthetic peptide. It was designed to imitate waglerin-1, a peptide found in the venom of the temple viper (Tropidolaemus wagleri). According to PubMed-indexed research, waglerin-1 is a competitive antagonist of the muscle nicotinic acetylcholine receptor, the receptor that lets a nerve tell a muscle to contract. Syn-Ake is sold as a gentler, needle-free way to borrow that muscle-relaxing idea for skincare. The venom research describes the natural toxin, not the cosmetic peptide, which is a far smaller and milder molecule.
What skin type is Syn-Ake best for?
Syn-Ake is aimed at people whose main concern is dynamic expression lines, such as forehead creases, frown lines, and crow's feet that appear with movement. As a peptide rather than an exfoliating acid, it is generally gentle and suits most skin types, including sensitive skin. It offers little for pigmentation, acne, or uneven texture, which call for different ingredients.
What does Syn-Ake do?
In laboratory work on the parent toxin, waglerin-1 binds selectively to the adult form of the muscle receptor, and it has served as a precise blocker of that receptor in muscle-tissue experiments. The cosmetic claim is that Syn-Ake mimics this effect weakly at the skin surface, briefly easing small muscle contractions so expression lines look softer. That idea is biologically plausible, but for the cosmetic peptide itself it rests largely on in-vitro and manufacturer testing rather than published independent human trials.
Some real-world case reports describe a serum pairing dipeptide diaminobutyroyl with acetyl hexapeptide-8, niacinamide, and polyhydroxy acids used alongside botulinum toxin injections, though that is an uncontrolled case series rather than a trial of Syn-Ake on its own.
How do you know if Syn-Ake can help your skin?
Syn-Ake is most likely to suit you if your lines are driven by movement and soften at rest. Deep static creases and sun damage respond little, and no topical peptide works like an injection. Give it roughly 8-12 weeks of consistent use, and keep expectations modest.
How do you use Syn-Ake?
Apply Syn-Ake to clean, dry skin, usually once or twice daily, in a serum or cream. Use it consistently rather than heavily, and remember that the surrounding formulation has a large say in how much peptide reaches the skin. Follow with a moisturizer, and apply sunscreen every morning.
What should you use with Syn-Ake?
Syn-Ake sits well with hydrating, barrier-supporting ingredients such as hyaluronic acid, niacinamide, and ceramides, and it is often blended with other peptides like acetyl hexapeptide-8 in "neuropeptide" serums. Daily broad-spectrum sunscreen does the most to prevent new lines, so it is the most valuable partner. If your skin is easily irritated, introduce strong actives one at a time.
Evidence strength
Limited: The mechanism behind Syn-Ake is grounded in solid pharmacology of the snake-venom peptide waglerin-1, but those studies examined the toxin in muscle tissue, not the cosmetic peptide on human skin. Published independent clinical trials of Syn-Ake itself are scarce, and much of the support is in-vitro or manufacturer-generated. Real-world results depend on the specific product and formulation, and whether the peptide penetrates intact skin to reach muscle is uncertain.
References
- Molles BE, Rezai P, Kline EF, McArdle JJ, Sine SM, Taylor P. Identification of Residues at the α and ε Subunit Interfaces Mediating Species Selectivity of Waglerin-1 for Nicotinic Acetylcholine Receptors. Journal of Biological Chemistry. 2002;277(7):5433-5440. doi:10.1074/jbc.M109232200
- Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P. Residues in the ε Subunit of the Nicotinic Acetylcholine Receptor Interact To Confer Selectivity of Waglerin-1 for the α−ε Subunit Interface Site. Biochemistry. 2002;41(25):7895-7906. doi:10.1021/bi025732d
- Teichert RW, Garcia CC, Potian JG, et al. Peptide‐Toxin Tools for Probing the Expression and Function of Fetal and Adult Subtypes of the Nicotinic Acetylcholine Receptor. Annals of the New York Academy of Sciences. 2008;1132(1):61-70. doi:10.1196/annals.1405.015
- Lee S, Yang Hs, Sasakawa T, et al. Immobilization with Atrophy Induces De Novo Expression of Neuronal Nicotinic α7 Acetylcholine Receptors in Muscle Contributing to Neurotransmission. Anesthesiology. 2014;120(1):76-85. doi:10.1097/ALN.0000000000000025
















